Noninfiltrating Intraductal Carcinoma (DCIS)

Subscribe to Selected New Research on Noninfiltrating Intraductal Carcinoma

1163 relevant articles (33 outcomes, 201 trials/studies) found for this Disease

Description: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.

Also Known As:

DCIS; Ductal Carcinoma In Situ; Intraductal Carcinoma; Carcinoma, Intraductal; Carcinoma, Intraductal, Noninfiltrating; Intraductal Carcinoma, Noninfiltrating; Carcinoma, Noninfiltrating Intraductal; Carcinomas, Intraductal; Carcinomas, Noninfiltrating Intraductal; Intraductal Carcinomas; Intraductal Carcinomas, Noninfiltrating; Noninfiltrating Intraductal Carcinomas

Relationship Network

Disease Context: Research Results

Neoplasms: 387349

Neoplasms by Histologic Type: 1

Glandular and Epithelial Neoplasms: 238

Carcinoma: 89391

Adenocarcinoma: 25820

Noninfiltrating Intraductal Carcinoma: 1163

Mammary Paget's Disease: 25

Neoplasms, Ductal, Lobular, and Medullary

Noninfiltrating Intraductal Carcinoma: 1163

Mammary Paget's Disease: 25

Related Diseases

1.	Noninfiltrating Intraductal Carcinoma (DCIS)
2.	Breast Neoplasms (Breast Cancer)
3.	Neoplasms (Cancer)
4.	Carcinoma (Carcinomatosis)
5.	Hyperplasia

Experts

1.	Kuerer, Henry M: 4 articles (08/2007 - 10/2003)
2.	Bundred, N J: 4 articles (04/2005 - 01/2001)
3.	Knox, W F: 4 articles (04/2005 - 01/2001)
4.	Altundag, Kadri: 3 articles (08/2007 - 07/2005)
5.	Meric-Bernstam, Funda: 3 articles (07/2007 - 10/2003)
6.	Diallo, Raihanatou: 3 articles (02/2006 - 10/2004)
7.	Jackisch, Christian: 3 articles (02/2006 - 10/2004)
8.	Poremba, Christopher: 3 articles (02/2006 - 10/2004)
9.	Rody, Achim: 3 articles (02/2006 - 10/2004)
10.	Sahin, Aysegul: 3 articles (04/2004 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Noninfiltrating Intraductal Carcinoma:

1.	Tamoxifen FDA LinkGeneric 09/01/2004 - "The role of adjuvant tamoxifen in the treatment of DCIS was evaluated in two RCTs: one demonstrated a significant reduction in IBTR with tamoxifen and the other did not" 08/01/2007 - "METHODS: We examined the records of 813 patients with localized DCIS and disease-negative margins after LE who were randomly assigned to no further therapy or to breast irradiation in National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-17 and 1799 patients randomized to receive placebo or tamoxifen after LE + radiotherapy in NSABP trial B-24" 05/01/2007 - "The BASO DCIS II trial assesses the benefit of adding radiotherapy in ER positive DCIS treated with 5 years Tamoxifen on local recurrence" 05/01/2007 - "Studies show that younger women (less than 50 years of age) have a significantly higher risk of recurrence after ductal carcinoma in situ treatment and tamoxifen is therefore recommended in women under 50 years of age who are undergoing wide local excision for ductal carcinoma in situ" 05/01/2007 - "Tamoxifen has been studied after wide local excision and radiotherapy in the NSABP24 trial and in the UK DCIS trial" Order ALL the reference details at left...
2.	Aromatase InhibitorsIBA 08/01/2007 - "The few clinical data that are available therefore suggest the aromatase inhibitors are likely to be effective in DCIS" 08/01/2007 - "This study has shown significant effects of aromatase inhibitors on DCIS indicating that these agents are therapeutically active in this condition." 08/01/2007 - "Within the DCIS both aromatase inhibitors significantly reduced PgR expression and both drugs also produced a significant fall in proliferation" 08/01/2007 - "DCIS and aromatase inhibitors." 06/01/2004 - "This review focuses on data on aromatase inhibitors in the adjuvant setting and looks to the future potential of these drugs in both ductal carcinoma in situ and chemoprevention." Order ALL the reference details at left...
3.	Estrogens (Estrogen)FDA Link 01/01/2008 - "In 1989 the reporting form for DCIS was extended and now provided information on histological subtype, malignancy grade, growth pattern and both Estrogen receptor (ER) and Progesteron receptor (PR) status" 11/01/2007 - "Patients with estrogen receptor (ER)-negative, human epidermal growth factor-2 (HER-2)-positive DCIS pose a treatment challenge" 03/01/2007 - "The following factors were evaluated for correlation with margins at initial excision: age (< or >45), grade (3/1 or 2), family history (present/absent), histology (lobular/other), estrogen receptor (ER) status, presence of extensive intraductal carcinoma (EIC), presence of lymphovascular invasion (LVI), and biopsy type (excisional/preoperative)" 10/01/2006 - "RESULTS: For DCIS cases, images that overestimated pathologic size had heterogeneous enhancement on MR, were estrogen receptor positive, and were low grade by pathology" 07/01/2005 - "Challenge in the treatment of estrogen-receptor-negative ductal carcinoma in situ." Order ALL the reference details at left...
4.	anastrozole (Arimidex)FDA Link 09/06/2003 - "Anastrozole for ductal carcinoma in situ." 01/01/2003 - "The potential role of anastrozole in the neoadjuvant setting, the management of DCIS, premenopausal breast cancer and breast cancer prevention is currently being investigated." 01/01/2003 - "A parallel trial will compare anastrozole against tamoxifen in 4,000 women with locally excised DCIS." 08/01/2007 - "In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer" 02/01/2005 - "Anastrozole significantly reduced contralateral breast cancer compared with tamoxifen, and this has led to two prevention trials: one in women at risk comparing anastrozole with placebo and the other after excision of DCIS comparing anastrozole with tamoxifen (IBIS II)" Order ALL the reference details at left...
5.	Aromatase (CYP19)IBA 01/01/2008 - "CONCLUSION: We have demonstrated the presence of both aromatase and EST in malignant epithelium and adjacent stromal fibroblasts in DCIS" 01/01/2008 - "Whereas no significant difference was observed for epithelial aromatase expression in high versus non-high grade DCIS (P = 0.735 Chi square test), epithelial EST levels were found to be significantly down-regulated in high-grade DCIS compared to non-high grade cases (P = 0.042)" 01/01/2008 - "However, stromal aromatase expression was significantly higher in IBC compared to adjacent DCIS components (P = 0.034, Chi square test)" 01/01/2008 - "RESULTS: We found that aromatase was equally detectable in epithelial components of both, DCIS and IBC (P = 0.884, Chi square test)" 07/01/2002 - "Among the DCIS samples, those specimens from patients of ages 50 years or over showed higher levels of aromatase expression in stromal cells, than those from patients below 50 years" Order ALL the reference details at left...
6.	HormonesIBA 09/01/2001 - "Recent studies have shown that ER-negative DCIS, unlike ER-positive DCIS, is hormone independent and does not respond to anti-oestrogen treatment" 10/01/2008 - "The biological behavior of DCIS has been associated with distinct molecular and histological features (such as expression of COX2, Ki67, c-erbB2, p53 mutation, presence or absence of comedonecrosis, nuclear grade, hormone receptor status, etc.)" 01/01/2004 - "We have initiated a clinical trial of neoadjuvant hormonal therapy for women with hormone receptor-positive DCIS" 07/21/2003 - "In conclusion, a biological response to hormone manipulation is only seen in OR-positive DCIS tumours" 11/01/2002 - "The sizeable proportion of hormone receptor-negative tumours may have implications for the hormonal adjuvant therapy of DCIS." Order ALL the reference details at left...
7.	trastuzumab (Herceptin)FDA Link 01/01/2007 - "Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression." 08/01/2007 - "Studies in the treatment of DCIS exploring partial breast radiation and trastuzumab are under way" 01/01/2007 - "To test this hypothesis, a trial of neoadjuvant trastuzumab for DCIS has been opened at our institution" 11/01/2007 - "Trastuzumab not for ductal carcinoma in situ?" 01/01/2007 - "Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)." Order ALL the reference details at left...
8.	DNA (Deoxyribonucleic Acid)IBA 12/01/1997 - "Histopathologic features, including DNA studies, do not reliably predict the pathologic extent of DCIS, but mammographic size and focality do significantly correlate with pathologic size" 10/01/1995 - "The median tumour size was 12 mm. The aim of the study was to support, with a larger sample, our recent findings with respect to DNA ploidy pattern in the selected group of ICs with predominance of DCIS (group I)" 01/01/2003 - "No significant differences, in neither morphology, immunohistochemistry, nor DNA ploidy, were shown between DCIS without and with invasion" 01/01/2003 - "Small nuclear CIS, whether LCIS or DCIS, on the contrary, were DNA diploid with low proliferation, and no cases showed overexpression of c-erbB-2 and p53" 01/01/2003 - "Partial or complete concordance in DNA ploidy between DCIS and IC within the individual case was found in most cases, except for the additional presence in the IC component of DNA hyperdiploid clones that might possibly be of importance for the process of invasion" Order ALL the reference details at left...
9.	Cyclin D1IBA 07/01/2000 - "These results suggest that Cyclin D1 expression may play an important role in the early stages of carcinogenesis, and that immunohistochemical detection of Cyclin D1 expression may be helpful in differentiating low-grade DCIS from ADH." 02/01/2006 - "In all, 33, 15, 32, and 60% of ductal carcinoma in-situ showed overexpression of Akt, FKHR, mTOR, and cyclin D1" 02/01/2005 - "DH and DCIS but not normal ductal structures showed an increased percentage of cells with nuclear-localized cyclin D1" 11/17/2003 - "In summary, using a tissue array approach we have shown that cyclin D1, besides growth pattern, is a prognostic marker for local recurrence in DCIS." 09/01/2003 - "Higher levels of expression of cyclin D1 and p21(WAF1/CIP1) were observed in DCIS than in the adjacent epithelia" Order ALL the reference details at left...
10.	Estrogen Receptor Modulators (Antiestrogen)IBA 07/01/1990 - "Since only 70 per cent of positive receptor lesions are expected to respond to antiestrogens, it appears that only 40 per cent of patients with ductal carcinoma in situ of breast will benefit from endocrine therapy." 02/01/1993 - "Because only 60% of the cases have detectable ER and approximately 70% of positively stained ERs are expected to be functional (as in invasive carcinoma), it appears that approximately 42% of the patient population with DCIS will benefit from antiestrogen therapy." 07/01/1990 - "A number of investigators have suggested treatment of precursor lesions for invasive breast cancer such as ductal carcinoma in situ with antiestrogen" 08/01/2000 - "Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS)" 02/01/1993 - "Long-term antiestrogen therapy has been suggested as a possible treatment alternative for ductal carcinoma in situ (DCIS) of the breast" Order ALL the reference details at left...

Therapies and Procedures

1.	Segmental Mastectomy (Lumpectomy) 09/01/2001 - "The pattern of duct distribution was important: DCIS in which the involved ducts were more widely separated had a significantly greater recurrence of DCIS than when the involved ducts were more concentrated (p=0.08 for mammographically detected DCIS, p=0.07 for patients who underwent lumpectomy alone)" 06/01/2002 - "MAIN MESSAGE: Lumpectomy followed by radiation is effective treatment for DCIS" 05/01/2007 - "None of the previous trials which compared radiotherapy with breast conserving surgery alone have achieved clear margin status in all patients and analysis of their data suggests that the recurrence rate when clear margins around the ductal carcinoma in situ are achieved is low (approximately 10% at six years)" 01/01/2007 - "Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials." 05/01/2005 - "The objective of this study was to examine the implications of DCIS found in the original CB, specifically related to the risk of EIC and/or positive lumpectomy margins" Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 08/01/2004 - "Since many issues are controversial such as the prognostic value of micrometastases and extramammary nodes as well as the use of SNB after primary chemotherapy and in ductal carcinoma in situ, further clinical studies are necessary." 02/01/2006 - "The use of sentinel lymph node biopsy with neoadjuvant chemotherapy and ductal carcinoma in situ continues to undergo investigation" 07/01/2004 - "The success rate of SLN biopsy after neoadjuvant chemotherapy was investigated as well as the percentage of positive SLNs in patients with DCIS" 02/01/2004 - "New questions, such as the feasibility of neoadjuvant chemotherapy in improving breast conserving rate, the appropriateness of breast conservation treatment in ductal carcinoma in situ, the effectiveness of radiation therapy in patients treated by breast conservation, and patient selection for breast conservation without radiation, are now being raised" 08/01/2000 - "RESULTS: Forty-three (9%, two bilateral) of the 487 patients did not receive radiation; 9 because of advanced age, 8 refused, 7 had severe intercurrent diseases, 6 developed stage IV disease while getting chemotherapy for stage III disease, 5 patients (1 bilateral) had two reasons for omission (3 cases: age + intercurrent disease; 2 cases: age + stage IV disease; and 1 case: age + small focus of ductal carcinoma in situ) and the remainder for miscellaneous reasons" Order ALL the reference details at left...
3.	Mastectomy (Mammectomy) 01/01/2004 - "There are indications from clinical studies that excision plus radiation therapy is as effective as mastectomy in reducing recurrence in patients with low-risk DCIS" 10/01/2008 - "In multiple studies, SSM seems to be oncologically safe in patients undergoing mastectomy for invasive T1-T2 tumours, multicentric tumours, ductal carcinoma in situ or risk-reduction" 03/01/2007 - "CONCLUSIONS: Our study corroborates previous reports on the persistent rates of mastectomy and axillary nodal dissection and the limited use of XRT in the treatment of DCIS." 02/01/2007 - "The purpose of this study was to determine factors associated with the subsequent diagnosis of invasive disease and to determine the role of SLNB when performing a mastectomy for DCIS" 09/01/2001 - "Overall, 52.5% of study subjects received a mastectomy (48.9%, 45.8%, and 73.5% of women with DCIS, local disease, and regional disease, respectively, p < 0.05)" Order ALL the reference details at left...
4.	Adjuvant Radiotherapy 02/01/2003 - "Three recent randomized controlled trials have demonstrated that adjuvant radiotherapy (RT) after adequate local excision of localized DCIS significantly reduces the incidence of local recurrence" 06/01/2007 - "In multivariate analysis, p53 overexpression (HR 3.0, 95% CI 1.1-8.2, P = 0.036 and HR 4.4, 95% CI 1.5-12.9, P = 0.008) and adjuvant radiotherapy (HR 0.2, 95% CI 0.1-0.8, P = 0.026) were independent common predictors of LR in patients who had received treatment for both DCIS and IDC" 04/01/2006 - "DISCUSSION: All patients with DCIS have potential benefit to gain from adjuvant radiotherapy" 03/01/2005 - "The main controversies surrounding the management of DCIS evolve around the need for adjuvant radiotherapy (RT) after adequate local excision (LE) of localized lesions and the role of adjuvant endocrine therapy" 09/01/2004 - "The main controversies surrounding the management of DCIS evolve around the need for adjuvant radiotherapy (RT) after adequate local excision (LE) of localized lesions and the role of adjuvant endocrine therapy" Order ALL the reference details at left...
5.	Chemoprevention 05/01/2005 - "It could be tested in future prospective trials of chemoprevention or ductal carcinoma in situ adjuvant hormonotherapy." 01/01/2006 - "CONCLUSION: The risk of CBC development is higher with concurrent ADH than in patients with DCIS alone, and these patients may therefore be appropriate candidates for additional chemoprevention strategies" 08/01/2001 - "Endocrine therapy will doubtless become more important for adjuvant therapy of DCIS as well as chemoprophylaxis in the future" 01/01/1996 - "Classification of duct carcinoma in situ (DCIS) with a characterization of high grade lesions: defining cohorts for chemoprevention trials." 08/01/2002 - "Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Noninfiltrating Intraductal Carcinoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 33 Outcomes
Top 200 Key Drugs and Biologics
Top 35 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>